67 results
424B3
XRTX
XORTX Therapeutics Inc
13 Jun 24
Prospectus supplement
4:19pm
and/or reimbursement, as well as evaluate product brand name selection and prepare related filings and conduct other launch preparation activities. This work … to facilitate the path to potential approval of XORLOTM in the EU, including required clinical studies and reimbursement conditions. This work will be ongoing
424B3
XRTX
XORTX Therapeutics Inc
13 Jun 24
Prospectus supplement
4:18pm
product candidates in the United States and internationally, if licensed for marketing, reimbursement, sale and distribution in such countries … authorities in other jurisdictions. In many jurisdictions outside the United States, a product candidate must be approved for reimbursement before
424B3
XRTX
XORTX Therapeutics Inc
13 Jun 24
Prospectus supplement
4:17pm
in excess of $120,000 other than for (i) payment of salary or consulting fees for services rendered, (ii) reimbursement for expenses incurred on behalf
424B3
XRTX
XORTX Therapeutics Inc
13 Jun 24
Prospectus supplement
4:15pm
in-depth analysis of pricing and/or reimbursement, as well as evaluate product brand name selection and prepare related filings, and conduct other … and reimbursement conditions. This work will be ongoing from 2023 through 2026, and will include a future request for orphan drug status. In addition, XORTX
424B3
XRTX
XORTX Therapeutics Inc
13 Jun 24
Prospectus supplement
4:12pm
and/or reimbursement, as well as evaluate product brand name selection and prepare related filings and conduct other launch preparation activities. This work … to facilitate the path to potential approval of XORLOTM in the EU, including required clinical studies and reimbursement conditions. This work
424B3
zpxf29z454
13 Jun 24
Prospectus supplement
4:11pm
424B3
7xk1hb 1wxv
13 Jun 24
Prospectus supplement
4:10pm
424B3
4dlz2elkbph0
13 Jun 24
Prospectus supplement
4:10pm
6-K
EX-99.2
ry0yp d6t
16 May 24
Condensed Interim Consolidated Financial Statements
6:45pm
6-K
EX-10.1
8cu6 oa3lnhubfpv
30 Nov 23
XORTX Announces US ATM Offering
4:04pm
424B5
egb3m8yq3rdsi1e
29 Nov 23
Prospectus supplement for primary offering
9:57pm
6-K
EX-99.2
88an5cw1
15 Nov 23
Condensed Interim Consolidated Financial Statements
9:30pm
424B3
17o5 zubh80zxxbj
25 Aug 23
Prospectus supplement
6:00am
424B3
300ddtw 6w8a1ztz3hw
25 Aug 23
Prospectus supplement
6:00am
6-K
EX-99.2
8sn7j2ui8h80
15 Aug 23
Condensed Interim Consolidated Financial Statements
6:00am